M.D. Orçun Can is a medical oncologist trained at Okmeydanı Training and Research Hospital, where he completed his specialty training in 2018. He has been practicing with Acıbadem Health Group since 2023, providing evidence-based cancer care and participating in multidisciplinary treatment planning. He is an active member of leading professional societies, including the Turkish Society of Medical Oncology (TTOD), the European Society for Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). These memberships reflect his commitment to staying current with international advances in oncology and to delivering high-quality, patient-centered care.
Education
- 2018 Okmeydanı Training and Research Hospital Medical Oncology
- 2014 Medeniyet University Göztepe Training and Research Hospital Internal Medicine
- 2009 Cukurova University Faculty of Medicine
Experience
- 2023 Acibadem Health Group
- 2018 – 2021 Istanbul Prof. Dr. Cemil Tascioglu City Hospital / Medical Oncology / Specialist Doctor
- 2018 Nevşehir State Hospital / Medical Oncology / Specialist Doctor
- 2015 – 2018 Istanbul Okmeydanı Training and Research Hospital / Assistant
- 2014 – 2015 Kirklareli Pinarhisar State Hospital / Internal Medicine / Specialist Doctor
- 2009 Mersin Tarsus Çiçekli Health Center / General Practitioner
Memberships
- TTOD (Turkish Society of Medical Oncology)
- ESMO (European Society for Medical Oncology)
- ASCO (American Society of Clinical Oncology)
Publications
- Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium
Urologia Internationalis, 107(6), 595-601., Doi: 10.1159/000528994 (Publication No: 8436265) (2023) EROL CİHAN, YEKEDUZ EMRE, TURAL DENİZ, KARAKAYA SERDAR, ŞENTÜRK ÖZTAŞ NİHAN, UÇAR GÖKHAN, KILIÇKAP SADETTİN, ERTÜRK İSMAİL, SEVER ÖZLEM NURAY, ARSL - External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database
Clinical Genitourinary Cancer, 21(1), 175-182., Doi: 10.1016/j.clgc.2022.07.006 (Publication No: 8124532) (2023) YEKEDÜZ EMRE, KARAKAYA SERDAR, ERTÜRK İSMAİL, TURAL DENİZ, UÇAR GÖKHAN, ŞENTÜRK ÖZTAŞ NİHAN, ARIKAN RUKİYE, HIZAL MUTLU, KÜÇÜKARDA AHMET, SEVER ÖZL - How reliable is the high-volume definition in prostate cancer patients: the potential game-changing role of PSMA
Nuclear Medicine Communications, 44(9), 816-824., Doi: 10.1097/MNM.0000000000001722 (Publication No: 8436253 (2023)) GÜVEN OSMAN, KARYAĞAR SAVAŞ, ARICI SERDAR, ÖZÜLKER TAMER, CAN ORÇUN - Serum fetuin-A and RANKL levels in patients with early stage breast cancer
Journal of Medical Biochemistry, 42(2), 249-257., Doi: 10.5937/jomb0-37386 (Publication No: 8436129) (2023) AVŞAR USUL ÇİĞDEM, ARAL HALE, CAN ORÇUN, CAN TRABLUS DİDEM, KARAÇETİN DİDEM, NAZLI MEHMET ALİ, GÜRSU RIZA UMAR, KARABULUT SENEM - Efficacy of Imatinib on Advanced and Refractory Desmoid Tumors: A Retrospective Study.
Journal of Oncological Sciences (JOS), 8(2), 63-68., Doi: 10.37047/jos.2021-87391 (Control No: 8214846) (2022) ATCI MUHAMMED MUSTAFA, CAN ORÇUN, SEÇMELER ŞABAN, SAKİN ABDULLAH, AY ERSOY SEVAL, CİHAN ŞENER, SELVİ OĞUZHAN, GEREDELİ ÇAĞLAYAN - The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab i in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study
Journal of Cancer Research and Clinical Oncology, 148(12), 3537-3546., Doi: 10.1007/s00432-022-04055-5 (Publication No: 7696517) (2022) YEKEDÜZ EMRE, TURAL DENİZ, ERTÜRK İSMAİL, KARAKAYA SERDAR, EROL CİHAN, ERCELEP ÖZLEM, ARSLAN ÇAĞATAY, SEVER ÖZLEM NURAY, KILIÇKAP SAADETTİN, ŞENTÜR - The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors.
Scientific Reports, 12(1), 1-9., Doi: 10.1038/s41598-022-20056-3 (Publication No: 7307182) (2022) BİR YÜCEL KADRİYE, YEKEDÜZ EMRE, KARAKAYA SERDAR, TURAL DENİZ, ERTÜRK İSMAİL, EROL CİHAN, ERCELEP ÖZLEM, ŞENTÜRK ÖZTAŞ NİHAN, ARSLAN ÇAĞATAY, UÇAR - Efect of Adjuvant Chemotherapy in Stage III Cervical Cancer Patients Treated with Concurrent Chemoradiation: A Multicenter Study
Oncology Research and Treatment, 45(5), 254-261., Doi: 10.1159/000521980 (Publication No: 7571177) (2022) ATÇI MUHAMMED MUSTAFA, AKAGÜNDÜZ BARAN, DEMİR METİN, DÖNMEZ YILMAZ BİNNUR, AKIN TELLİ TUĞBA, CAN ORÇUN, ÇİL İBRAHİM, GÖKTAŞ AYDIN SABİN, ÖZYURT NES - Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.
Future Oncology, 17(35), 4861-4869., Doi: 10.2217/fon-2021-0717 (Publication No: 7506054) (2021) YEKEDÜZ EMRE, ERTÜRK İSMAİL, TURAL DENİZ, KARADURMUŞ NURİ, KARAKAYA SERDAR, HIZAL MUTLU, ARIKAN RUKİYE, ARSLAN ÇAĞATAY, TABAN HAKAN, KÜÇÜKARDA AHME - Survival and Prognostic Factors in Limited-stage Small-cell Lung Cancer.
JCPSP-Journal of The College of Physicians and Surgeons Pakistan, 31(12), 1433-1437., Doi: 10.29271/jcpsp.2021.12.1433 (Publication No: 8215561) (2021) ATCI MUHAMMED MUSTAFA, SAKİN ABDULLAH, UYSAL EMRE, AKSARAY FERDİ, SELVİ OĞUZHAN, CAN ORÇUN
